Yahoo · Oct 27, 2026
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says
Xencor's (XNCR) shares have strong upside potential due to "exciting" phase 1 data that exceeded exp
XN
NASDAQ · XNCR
Xencor, Inc.
Healthcare · Biotechnology
$30.64
Up+$3.15 (+10.26%)
Updated Nov 4, 2026, 5:44 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.22B
- P/E ratio
- -7.12
- Dividend yield
- 0.00%
- 52-week range
- $10.38 – $33.60
- Volume
- 1.22M
- Avg. volume
- 1.16M
Price performance · XNCR
XNCR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
XNCR closed at $30.64 after 21 trading sessions, up 25.78% for the selected period.
- Last close
- $30.64
- Period change
- +25.78%
- Period low
- $22.85
- Period high
- $30.64
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $29.61 | $31.1029 | $29.61 | $30.64 | 1.22M |
| Nov 2, 2026 | $30.00 | $30.24 | $29.08 | $29.66 | 2.11M |
| Oct 30, 2026 | $29.09 | $30.045 | $28.61 | $29.82 | 1.29M |
| Oct 29, 2026 | $30.08 | $30.56 | $28.92 | $29.21 | 931.2K |
| Oct 28, 2026 | $29.65 | $30.72 | $29.2644 | $29.99 | 1.38M |
| Oct 27, 2026 | $29.74 | $30.25 | $27.76 | $29.99 | 2.11M |
| Oct 26, 2026 | $32.31 | $33.60 | $28.84 | $29.18 | 8.9M |
| Oct 23, 2026 | $25.52 | $25.81 | $24.42 | $25.18 | 1.46M |
| Oct 22, 2026 | $25.18 | $26.12 | $24.71 | $25.84 | 936.35K |
| Oct 21, 2026 | $25.40 | $25.50 | $24.42 | $25.16 | 1.48M |
| Oct 20, 2026 | $23.25 | $25.01 | $23.25 | $24.94 | 884.2K |
| Oct 19, 2026 | $22.99 | $23.49 | $21.97 | $23.19 | 2.04M |
| Oct 16, 2026 | $24.02 | $24.21 | $22.76 | $22.85 | 1.13M |
| Oct 15, 2026 | $23.14 | $24.30 | $23.14 | $24.00 | 726.92K |
| Oct 14, 2026 | $23.43 | $24.26 | $23.215 | $23.39 | 1.37M |
| Oct 13, 2026 | $25.00 | $25.16 | $23.33 | $23.52 | 2.43M |
| Oct 12, 2026 | $24.64 | $25.32 | $24.435 | $25.04 | 753.05K |
| Oct 9, 2026 | $24.43 | $25.38 | $24.353 | $24.63 | 1.15M |
| Oct 8, 2026 | $24.02 | $24.56 | $22.56 | $24.50 | 2.19M |
| Oct 7, 2026 | $24.11 | $24.59 | $23.66 | $24.26 | 1.7M |
| Oct 6, 2026 | $25.76 | $26.03 | $23.89 | $24.36 | 1.25M |
Latest XNCR news
The latest Smart Investors Daily articles mentioning XNCR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
XNCR research
Overview
Company profile and research snapshot.
Company profile
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | RBC Capital | Outperform | — |
| Oct 27, 2026 | Wedbush | Outperform | — |
| Oct 27, 2026 | Wells Fargo | Overweight | — |
| Oct 27, 2026 | Truist Securities | Buy | — |
| Oct 21, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 27, 2026
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40
Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $29 to $40.
Benzinga · Oct 27, 2026
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43
RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $20 to $43.
Benzinga · Oct 27, 2026
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44
Wells Fargo analyst Derek Archila maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $30 to $44.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
